MC-Sq-Cit-PAB-Gefitinib |
Catalog No.GC36564 |
MC-Sq-Cit-PAB-Gefitinib est un conjugué médicament-lieur pour l'ADC avec une puissante activité antitumorale en utilisant le Gefitinib (un inhibiteur de la tyrosine kinase EGFR), lié via le lieur ADC MC-Sq-Cit-PAB.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1941168-63-3
Sample solution is provided at 25 µL, 10mM.
MC-Sq-Cit-PAB-Gefitinib has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Sq-Cit-PAB-Gefitinib is used for the antibody-drug conjugates (ADC) to treat various diseases or disorders, e.g. characterized by the overexpression of a tumor antigen[1,2].
[1]. FLYGARE, John A, et al. Quaternary amine compounds and antibody-drug conjugates thereof. WO2016090050A1. [2]. Staben LR, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem. 2016 Dec;8(12):1112-1119.
Average Rating: 5
(Based on Reviews and 4 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *